Bristol Myers Squibb (NYSE:BMY) EVP David Elkins Sells 30,000 Shares

Bristol Myers Squibb Company (NYSE:BMY) EVP David Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $59.57 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The company has a market cap of $121.63 billion, a PE ratio of 17.27, a price-to-earnings-growth ratio of 0.18 and a beta of 0.27. The company has a 50 day moving average of $59.27 and a 200-day moving average of $52.57. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period last year, the business earned $1.67 earnings per share. The business’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 data for Camzyos (SCOUT‑HCM) in adolescents may expand the label/profile for BMY’s cardiac myosin inhibitor, strengthening the late‑stage pipeline and future revenue potential. SCOUT‑HCM Trial Results
• Positive Sentiment: Janux Therapeutics triggered a $35M milestone under its collaboration with BMY after nominating a development candidate — a near‑term cash/partner validation and a de‑risking signal for partnered R&D. Janux Milestone
• Positive Sentiment: Unusually large call‑option activity (≈66,900 calls traded) indicates speculative bullish interest from traders positioning for upside. (Market data entry)
• Positive Sentiment: Analyst commentary and screens (Zacks/Trefis pieces) highlight BMY’s history of earnings surprises and a view that the company has ingredients to beat upcoming results — supportive for investor sentiment. Analyst Coverage
• Neutral Sentiment: Analyses project HNSCC market growth to ~$4.5B by 2034 (CAGR ≈8.4%), a long‑term addressable market note that may matter if BMY advances therapies in that space. HNSCC Market Outlook
• Neutral Sentiment: Reports on growth in the advanced renal cell carcinoma market highlight broader oncology tailwinds that include BMY among peers — useful context but not an immediate stock catalyst. RCC Market Report
• Neutral Sentiment: BMY published community and program updates around multiple myeloma care and equity initiatives — positive for ESG/community positioning but unlikely to move near‑term revenue. Community Program Release
• Negative Sentiment: Insider selling: EVP David V. Elkins sold 30,000 shares at ~$61.67 on April 1 (Form 4 filing), reducing his stake ~15.9% — an action investors may view negatively even if it’s routine. Insider Form 4
• Negative Sentiment: Recent quarterly results (reported Feb. 5) showed an EPS miss ($1.26 vs. $1.65 est.), even as revenue slightly beat; that earnings disappointment and investor focus on near‑term profitability remain headwinds despite FY‑26 guidance of $6.05–$6.35. (Company filings/earnings release)

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective for the company. Citigroup upped their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Piper Sandler restated an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Finally, Guggenheim reaffirmed a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average price target of $61.41.

Hedge Funds Weigh In On Bristol Myers Squibb

Several large investors have recently modified their holdings of the business. Brighton Jones LLC grew its stake in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 2,786 shares during the period. United Bank grew its position in shares of Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after buying an additional 3,277 shares during the last quarter. VestGen Advisors LLC increased its stake in shares of Bristol Myers Squibb by 18.7% in the second quarter. VestGen Advisors LLC now owns 4,474 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 706 shares during the period. Finally, Fisher Asset Management LLC raised its position in shares of Bristol Myers Squibb by 2.8% during the second quarter. Fisher Asset Management LLC now owns 226,976 shares of the biopharmaceutical company’s stock worth $10,507,000 after acquiring an additional 6,237 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.